- Home
- EDUC vs IMRN Comparison
EDUC vs IMRN Comparison
Compare EDUC & IMRN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EDUC
- IMRN
- Stock Information
- Founded
- EDUC 1965
- IMRN 1994
- Country
- EDUC United States
- IMRN Australia
- Employees
- EDUC N/A
- IMRN N/A
- Industry
- EDUC Consumer Specialties
- IMRN Biotechnology: Pharmaceutical Preparations
- Sector
- EDUC Consumer Discretionary
- IMRN Health Care
- Exchange
- EDUC Nasdaq
- IMRN Nasdaq
- Market Cap
- EDUC 11.4M
- IMRN 9.2M
- IPO Year
- EDUC N/A
- IMRN N/A
- Fundamental
- Price
- EDUC $1.33
- IMRN $1.88
- Analyst Decision
- EDUC
- IMRN Strong Buy
- Analyst Count
- EDUC 0
- IMRN 1
- Target Price
- EDUC N/A
- IMRN $5.00
- AVG Volume (30 Days)
- EDUC 5.6K
- IMRN 25.2K
- Earning Date
- EDUC 07-10-2025
- IMRN 07-07-2025
- Dividend Yield
- EDUC N/A
- IMRN N/A
- EPS Growth
- EDUC N/A
- IMRN N/A
- EPS
- EDUC N/A
- IMRN N/A
- Revenue
- EDUC $34,191,000.00
- IMRN $4,048,286.00
- Revenue This Year
- EDUC N/A
- IMRN N/A
- Revenue Next Year
- EDUC N/A
- IMRN N/A
- P/E Ratio
- EDUC N/A
- IMRN N/A
- Revenue Growth
- EDUC N/A
- IMRN 82.90
- 52 Week Low
- EDUC $0.92
- IMRN $1.50
- 52 Week High
- EDUC $2.49
- IMRN $2.87
- Technical
- Relative Strength Index (RSI)
- EDUC 54.39
- IMRN 58.70
- Support Level
- EDUC $1.32
- IMRN $1.68
- Resistance Level
- EDUC $1.46
- IMRN $1.94
- Average True Range (ATR)
- EDUC 0.07
- IMRN 0.09
- MACD
- EDUC -0.00
- IMRN 0.02
- Stochastic Oscillator
- EDUC 35.00
- IMRN 76.92
About EDUC Educational Development Corporation
Educational Development Corp is the United States trade publisher of the line of educational children's books produced in the United Kingdom. Its business activity functions with two reportable segments: PaperPie and Publishing. The Publishing Division segment markets its products to retail accounts, which include books, school supplies, toy and gift stores and museums, through commissioned sales representatives, trade and specialty wholesalers and an internal telesales group.
About IMRN Immuron Limited
Immuron Ltd is a commercial and clinical-stage biopharmaceutical company focused on the development and commercialization of a novel class of immunomodulator polyclonal antibodies to treat liver diseases, infectious diseases and other immune-mediated diseases, such as colitis. The company's product, IMM-124E, is a proprietary immunomodulatory agent targeted at GI immune-mediated diseases including fatty liver diseases. The company functions in two segments namely, Research and Development and Hyperimmune products.